Timeline

1st generation prototype
First generation prototype of JEDI (TRL 3-4)
2020
Ex-vivo validation
Validation of JEDI underlying technology in animal joints.
2021
Terkko Health X – 1st place
Biomedical Spectroscopy Lab, the team behind JEDI, emerged as the top of 7 team at the annual Terkko Health X pre-accelerator programme
2021
Tahko Skii Lift – top 5 teams
Biomedical Spectroscopy Lab emerged as one of the top 5 teams in the 2021 edition of the Tahko Skii Lift competition.
2021
SPARK Finland
JEDI innovation accepted and inducted into SPARK Finland mentorship program.
2022
R2B funding
The aim of the R2B project funding is to assess the optimal pathway for commercialization of JEDI innovation.
2023
Bionnial Germany
Pitching JEDI innovation at the annual Bioannial event in Berlin, Germany.
2023
NLS Days 2024
Pitching JEDI innovation at the annual Nordic Life Science Days, Malmö, Sweden.
2024
NIF 2024
Networking and discussion with investors at the annual Nordic Innovation Fair in Copenhagen, Denmark.
2024
JEDI Pre-clinical test
Validation of JEDI using human samples and in human cadaver joints
2024
JEDI 2nd generation prototype
Development of the 2nd generation prototype of JEDI (TRL5-6).
2024
JEDI Diagnostic Software
Development of the JEDI diagnostic software for live evaluation of tissue integrity in surgery (TRL5-6).
2024
Patent filing
Filing of IPR generated from the JEDI R2B project.
2025

JEDI is a Research to Business project funded by Business Finland to commercialize the research innovation from the Biomedical Spectroscopy Lab, University of Eastern Finland, Kuopio, Finland. The project’s mission will be to develop solutions that will revolutionize orthopaedic surgery through evidence-based diagnostics by enabling rapid and non-destructive diagnosis of tissue pathology without compromising workflows.

The ultimate goal is to develop novel technologies to support clinicians in delivering optimal to enable better patient outcomes. Upon completion of the project, the optimal commercialisation pathway for JEDI to support objective assessment of tissue integrity during joint surgery will be determined and implemented.